Tofacitinib and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Tofacitinib (tofacitinib), especially for people who are female, 40-49 old, also take Methotrexate, and have Rheumatoid arthritis.

The study is created by eHealthMe based on reports of 5,544 people who have side effects when taking Tofacitinib from the FDA, and is updated regularly.

What is Tofacitinib?

Tofacitinib has active ingredients of tofacitinib. eHealthMe is studying from 5,554 Tofacitinib users. Check the latest studies of Tofacitinib.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

5,544 people reported to have side effects when taking Tofacitinib.
Among them, 56 people (1.01%) died.

Among these 56 people:

What is the gender of people who died when taking Tofacitinib? *

female: 69.77 %
male: 30.23 %

What is the age of people who died when taking Tofacitinib? *

What are other drugs people take besides Tofacitinib? *

What are other side effects people have before they died? *

Fatigue (feeling of tiredness): 9 people, 16.07%
Apathy: 7 people, 12.50%
Urge Incontinence (urinary incontinence): 7 people, 12.50%
Enlarged Prostate: 7 people, 12.50%
Listless (lack of interest, energy, or spirit): 7 people, 12.50%
Drug Ineffective: 6 people, 10.71%
Rashes (redness): 6 people, 10.71%
Drug Intolerance (drug sensitivity): 5 people, 8.93%
Herpes Zoster: 5 people, 8.93%
Upper Respiratory Tract Infection: 5 people, 8.93%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 45 people, 80.36%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 20 people, 35.71%
Psoriasis (immune-mediated disease that affects the skin): 14 people, 25.00%
Migraine (headache): 10 people, 17.86%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 5 people, 8.93%
Fibromyalgia (a long-term condition which causes pain all over the body): 3 people, 5.36%
Headache (pain in head): 3 people, 5.36%
Fever: 2 people, 3.57%
Interstitial Lung Disease: 2 people, 3.57%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 3.57%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tofacitinib:

Tofacitinib (5,554 reports)

Expand to all the drugs that have ingredients of tofacitinib:

Death and drugs with ingredients of tofacitinib

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tofacitinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,108 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib (the active ingredients of Tofacitinib) and Tofacitinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.